Literature DB >> 19869947

SPECIFIC CUTANEOUS REACTIONS AND CIRCULATING ANTIBODIES IN THE COURSE OF LOBAR PNEUMONIA : I. CASES RECEIVING NO SERUM THERAPY.

M Finland1, W D Sutliff.   

Abstract

1. A group of 41 non-serum treated patients with Type I, II or III pneumococcus pneumonia were studied during their disease and convalescence with respect to their skin reactions to specific pneumococcus polysaccharides and, in most instances, for the presence of circulating agglutinins and protective antibodies for all these 3 types. 2. One-half of the Type I and two-thirds of the Type II and Type III recovered cases gave the typical immediate "wheal and erythema" response to the homologous polysaccharide at or about the time of recovery. All cases tested showed protective antibodies and almost all showed agglutinins for the homologous pneumococcus. In the fatal cases, in general, positive cutaneous reactions and circulating antibodies were not obtained. 3. In cases of pneumonia receiving repeated cutaneous inoculations with various types of specific polysaccharide, antibodies for pneumococci differing from the infecting type but corresponding to the types of carbohydrate injected were present 1 week or later after such injections. These heterologous antibodies were most frequently demonstrated for Type II and were probably the result of immunization by means of the cutaneous injections. 4. Positive skin responses to homologous polysaccharides and corresponding circulating antibodies were demonstrated with similar frequency in the first 3 weeks after crisis in patients who had not previously received intracutaneous injections. In such patients heterologous antibodies were rarely found. 5. Typical skin reactions with the specific pneumococcus polysaccharides and mouse protective antibodies were demonstrated independently in a number of hospital patients who had had no recent history of pneumonia. 6. Some patients with demonstrable foci of persistent infection or with latent infections which later proved fatal showed positive cutaneous responses to the homologous type polysaccharide and circulating specific antibodies for the corresponding type. 7. The agglutination test, though less sensitive than the mouse protection test for determining the presence of antibody, has many advantages over the latter and is simplest to use in following the course of the untreated pneumonia.

Entities:  

Year:  1931        PMID: 19869947      PMCID: PMC2132063          DOI: 10.1084/jem.54.5.637

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  4 in total

1.  A RAPID METHOD FOR THE MACROSCOPIC AGGLUTINATION TEST.

Authors:  A Noble
Journal:  J Bacteriol       Date:  1927-11       Impact factor: 3.490

2.  CERTAIN ASPECTS OF MOUSE PROTECTION TESTS FOR ANTIBODY IN PNEUMOCOCCUS PNEUMONIA.

Authors:  F T Lord; E L Persons
Journal:  J Exp Med       Date:  1931-01-31       Impact factor: 14.307

3.  CUTANEOUS REACTIONS IN PNEUMONIA. THE DEVELOPMENT OF ANTIBODIES FOLLOWING THE INTRADERMAL INJECTION OF TYPE-SPECIFIC POLYSACCHARIDE.

Authors:  T Francis; W S Tillett
Journal:  J Exp Med       Date:  1930-09-30       Impact factor: 14.307

4.  CUTANEOUS REACTIONS TO THE POLYSACCHARIDES AND PROTEINS OF PNEUMOCOCCUS IN LOBAR PNEUMONIA.

Authors:  W S Tillett; T Francis
Journal:  J Exp Med       Date:  1929-10-31       Impact factor: 14.307

  4 in total
  8 in total

1.  A brief history of pneumococcal vaccines.

Authors:  R Austrian
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

2.  ANTIPNEUMOCOCCIC IMMUNITY REACTIONS IN INDIVIDUALS OF DIFFERENT AGES.

Authors:  W D Sutliff; M Finland
Journal:  J Exp Med       Date:  1932-05-31       Impact factor: 14.307

3.  SPECIFIC ANTIBODY RESPONSE OF HUMAN SUBJECTS TO INTRACUTANEOUS INJECTION OF PNEUMOCOCCUS PRODUCTS.

Authors:  M Finland; W D Sutliff
Journal:  J Exp Med       Date:  1932-05-31       Impact factor: 14.307

4.  SPECIFIC CUTANEOUS REACTIONS AND CIRCULATING ANTIBODIES IN THE COURSE OF LOBAR PNEUMONIA : II. CASES TREATED WITH ANTIPNEUMOCOCCIC SERA.

Authors:  M Finland; W D Sutliff
Journal:  J Exp Med       Date:  1931-10-31       Impact factor: 14.307

5.  STUDIES ON THE FLEXNER GROUP OF DYSENTERY BACILLI : III. ANTIBODY RESPONSE IN MAN FOLLOWING THE ADMINISTRATION OF THE SPECIFIC ANTIGEN OF TYPE V SHIGELLA PARADYSENTERIAE (FLEXNER).

Authors:  E Perlman; F Binkley; W F Goebel
Journal:  J Exp Med       Date:  1945-04-01       Impact factor: 14.307

6.  TESTS FOR PNEUMOCOCCUS HYPERSENSITIVENESS IN DOGS AFTER RECOVERY FROM EXPERIMENTAL PNEUMOCOCCUS LOBAR PNEUMONIA.

Authors:  L T Coggeshall
Journal:  J Exp Med       Date:  1935-01-31       Impact factor: 14.307

7.  THE VALUE OF THE SKIN TEST WITH TYPE-SPECIFIC CAPSULAR POLYSACCHARIDE IN THE SERUM TREATMENT OF TYPE I PNEUMOCOCCUS PNEUMONIA.

Authors:  T Francis
Journal:  J Exp Med       Date:  1933-03-31       Impact factor: 14.307

8.  IMMUNITY REACTIONS OF HUMAN SUBJECTS TO STRAINS OF PNEUMOCOCCI OTHER THAN TYPES I, II AND III.

Authors:  M Finland; W D Sutliff
Journal:  J Exp Med       Date:  1933-01-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.